KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

ClearPoint Neuro (CLPT) Long-Term Debt Issuances (2011 - 2025)

ClearPoint Neuro recorded quarterly Long-Term Debt Issuances of $19.4 million in Q4 2025, down 16.82% quarter-over-quarter from $23.4 million in Q4 2020.

ClearPoint Neuro's Long-Term Debt Issuances history runs 4 years deep, the most recent figure standing at $19.4 million for Q4 2025.

  • In Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to $19.4 million; the TTM figure through Dec 2025 stood at $19.4 million (down 16.82% YoY), while the FY2025 annual figure was $48.1 million, changed N/A from the prior year.
  • Long-Term Debt Issuances came in at $19.4 million for Q4 2025 at ClearPoint Neuro, down from $23.4 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $19.4 million in Q4 2025 to a low of $19.4 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 19.86 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 11.71 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 1.15 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 ClearPoint Neuro 375.84 Mn 340.24 Mn 7.76 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 19.43 Mn
Dec 31, 2025 19.43 Mn
Dec 31, 2020 23.36 Mn
Dec 31, 2020 23.36 Mn
Mar 31, 2012 3.42 Mn
Mar 31, 2012 3.42 Mn
Dec 31, 2011 -1.31 Mn
Dec 31, 2011 -1.31 Mn
Sep 30, 2011 810,000.00
Sep 30, 2011 810,000.00
Jun 30, 2011 500,000.00
Jun 30, 2011 500,000.00